Healthcare / Medical DistributionJakarta
$202.00
+2.00 (+0.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $144.9B · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
61/100
B
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.83T
P/E
7.1x
↓EV/EBITDA
3.3x
↓ROE
12.9%
↑Gross Margin
9.7%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.4%
FCF CAGR
+8.8%
FCF margin
2.0%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.89T · net income $392.27B · FCF $302.33B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14893.44B | $14893.44B | $14567.51B | $13092.03B | $11693.83B |
| Net Income | $392.27B | $392.27B | $345.03B | $305.89B | $311.83B |
| EBITDA | $605.23B | $605.23B | $562.40B | $499.16B | $496.73B |
| EPS | 30.17 | 30.17 | 24.62 | 21.83 | 22.25 |
| Gross Margin | 9.7% | 9.7% | 9.4% | 9.4% | 9.4% |
| Operating Margin | 3.3% | 3.3% | 3.2% | 3.1% | 3.5% |
| Net Margin | 2.6% | 2.6% | 2.4% | 2.3% | 2.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.11 | 0.10 | 0.23 |
| Current Ratio | 1.75 | 1.75 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $302.33B | $302.33B | $144.87B | $-242.25B | $234.71B |
| Returns | |||||
| ROE | 12.9% | 12.9% | 16.1% | 16.3% | 19.0% |
| Valuation | |||||
| P/E | 7.10 | 7.10 | — | — | — |
| EV/EBITDA | 3.33 | 3.33 | — | — | — |
| P/B | 0.87 | 0.87 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 2.2% | 2.2% | 11.3% | 12.0% | — |
| EPS Growth | 22.5% | 22.5% | 12.8% | -1.9% | — |
| Dividend Yield | 6.2% | 6.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-15.9%
EPS terminal req.
$17.92
Spread vs growth
38.5%
5Y implied EPS CAGR
-6.4%
EPS terminal req.
$21.69
Spread vs growth
28.9%
10Y implied EPS CAGR
1.5%
EPS terminal req.
$34.93
Spread vs growth
21.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+9.7%
Start / end P/E
8.0x → 6.8x
EPS bridge
24.62 → 30.17
Residual
-3.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.